The results of a subsequent phase III trial led to an accelerated approval from the United States Food and Drug Administration (FDA) of crizotinib as first-line therapy in ALK positive advanced NSCLC patients [21]. This evidence concerns the gene ALK and non-small cell lung carcinoma.